Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title previous answer version answering member constituency answering member printed answering member
tabling member	label

Search

1505861

registered interest
date	07/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Doctors: Registration
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 September to Question 45643, what data her Department regularly requires from the GMC on the number of currently licensed doctors, for the purposes of NHS workforce planning.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	49278
answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>The General Medical Council (GMC) is the independent regulator of all medical doctors practising in the United Kingdom which sets and enforces the standards all doctors must adhere to. The GMC is responsible for operational matters, including holding data on the number of currently licensed doctors. The Department does not require the GMC to provide data on the number of currently licensed doctors for National Health Service workforce planning.</p><p> </p><p>However, the Department accesses data published by the GMC, including at its online archive at the following link:</p><p>https://www.gmc-uk.org/about/what-we-do-and-why/data-and-research</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 11:50:02 answering member 4320 label Biography information for Robert Jenrick
tabling member	4769 label Biography information for Daisy Cooper

1506061

registered interest
date	07/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	West Hertfordshire Teaching Hospitals NHS Trust: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the three letters to hon Members representing Hertfordshire constituencies from the Minister of State Maria Caulfield, dated 6 September 2022, relating to the release of fees totalling £300,000 for planning, surveys and preparation work for West Hertfordshire Teaching Hospitals NHS Trust buildings, on what date she expects to release the £19.4 million required to commence the enabling works which was requested in October 2021.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	49280
answer	answer is ministerial correction date of answer 08/11/2022 answer text <p>All requests for enabling works require business cases, which are subject to the appropriate governance process to ensure effective appraisal and maximum value for taxpayers’ money. Individual funding allocations for enabling works will only be confirmed when the respective business case has been reviewed and agreed. We have received two business cases for a total of £19.4 million for West Hertfordshire NHS Trust, which are now being considered.</p> answering member constituency Colchester answering member printed Will Quince question first answered 08/11/2022 16:43:11 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1504891

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Respiratory Syncytial Virus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, on what date he expects NHS England’s Palivizumab Expert Group to respond to the request from the JCVI to consider the eligibility of children with spinal muscular atrophy to receive the Palivizumab vaccination against respiratory syncytial virus.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	47662
answer	answer is ministerial correction date of answer 20/09/2022 answer text <p>Respiratory syncytial virus (RSV) infection poses a serious risk for children with spinal muscular atrophy (SMA) with weakened respiratory muscles due to their condition. Following a letter from clinicians, the Joint Committee on Vaccination and Immunisation (JCVI) has requested that NHS England’s Palivizumab National Expert Group consider the eligibility of a sub-group of children with SMA to receive palivizumab vaccination this winter. This Group is preparing a briefing and on completion, it will meet and report the outcome of its discussion and recommendations to the JCVI. A specific date has yet to be confirmed.</p> answering member constituency Sleaford and North Hykeham answering member printed Dr Caroline Johnson grouped question UIN 47663 question first answered 20/09/2022 14:29:09 answering member 4592 label Biography information for Dr Caroline Johnson previous answer version 17723 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
tabling member	4769 label Biography information for Daisy Cooper

1504892

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Respiratory Syncytial Virus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to recommendations in the consensus statement of the 2017 International Conference on the Standards of Care on the use of Palivizumab for some categories of children with spinal muscular atrophy to protect from respiratory syncytial virus, if he will take steps to urgently review the eligibility criteria for the Palivizumab vaccine.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	47663
answer	answer is ministerial correction date of answer 20/09/2022 answer text <p>Respiratory syncytial virus (RSV) infection poses a serious risk for children with spinal muscular atrophy (SMA) with weakened respiratory muscles due to their condition. Following a letter from clinicians, the Joint Committee on Vaccination and Immunisation (JCVI) has requested that NHS England’s Palivizumab National Expert Group consider the eligibility of a sub-group of children with SMA to receive palivizumab vaccination this winter. This Group is preparing a briefing and on completion, it will meet and report the outcome of its discussion and recommendations to the JCVI. A specific date has yet to be confirmed.</p> answering member constituency Sleaford and North Hykeham answering member printed Dr Caroline Johnson grouped question UIN 47662 question first answered 20/09/2022 14:29:09 answering member 4592 label Biography information for Dr Caroline Johnson previous answer version 17724 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
tabling member	4769 label Biography information for Daisy Cooper

1504895

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if his Department will publish all evidence provided by immunologists to inform the decision not to procure Evusheld.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	47664
answer	answer is ministerial correction date of answer 22/09/2022 answer text <p>The Government has decided not to procure Evusheld for prevention through emergency routes at this time. This is a decision based on independent clinical advice by the multi-agency initiative, RAPID C-19 and a national expert policy working group. These groups considered a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies and concluded there is currently insufficient evidence of benefit to recommend deployment. The Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and agree that this should now be referred to the National Institute for Health and Care Excellence for further evaluation.</p><p>The Department intends to publish further details of the clinical advice received shortly.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 22/09/2022 15:37:32 answering member 4320 label Biography information for Robert Jenrick
tabling member	4769 label Biography information for Daisy Cooper

1504896

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the announcement on 12 August 2022 that Government will not be procuring any doses of Evusheld at this time, if he will set out in detail the decision making process including (a) what discussions were held by those responsible for making that decision, (b) what evidence informed that decision and (c) the rationale for that decision, in the four weeks before that procurement decision was taken.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	47665
answer	answer is ministerial correction date of answer 28/09/2022 answer text <p>The decision not to procure Evusheld at this present time for prevention through emergency routes is based on independent clinical advice by the multi-agency RAPID C-19 and a national expert policy working group. These groups considered a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies. RAPID C-19 monitors activity in clinical trials for emerging evidence and where treatments are proven to be clinically effective, enables access for National Health Service patients. The Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and it should now be referred to the National Institute for Health and Care Excellence for further evaluation. The Department intends to publish further details of the clinical advice received shortly.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 28/09/2022 15:55:41 answering member 4320 label Biography information for Robert Jenrick
tabling member	4769 label Biography information for Daisy Cooper

1504897

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the announcement on 12 August 2022 that Government will not be procuring any doses of Evusheld at this time, what assessment was made during the decision making process of the relevance of the data published on 29 July 2022 in the journal Clinical Infectious Diseases which showed that immunocompromised individuals administered with that drug were 92% less likely to be hospitalized or die than those who did not receive it.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	47666
answer	answer is ministerial correction date of answer 28/09/2022 answer text <p>The Government has decided not to procure Evusheld at this present time for prevention through emergency routes at this time. This is based on independent clinical advice by the multi-agency RAPID C-19 and a national expert policy working group. These groups considered a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies, including the study published on 29 July 2022 and concluded there is currently insufficient evidence of benefit against Omicron variants to recommend deployment. The Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and that this should now be referred to the National Institute for Health and Care Excellence for further evaluation.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 28/09/2022 16:12:56 answering member 4320 label Biography information for Robert Jenrick
tabling member	4769 label Biography information for Daisy Cooper

1504898

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will provide a list of members of the Rapid C-19 Oversight Group.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	47667
answer	answer is ministerial correction date of answer 22/09/2022 answer text <p>A list of the membership of the RAPID C-19 is attached.</p> answering member constituency Newark answering member printed Robert Jenrick grouped question UIN 47568 question first answered 22/09/2022 15:26:16 answering member 4320 label Biography information for Robert Jenrick attachment 1 file name RAPID-C19-oversight-group-membership.docx title RAPID C-19 oversight group membership
tabling member	4769 label Biography information for Daisy Cooper

1504899

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the announcement on 12 August 2022 that Government will not be procuring any doses of Evusheld at this time, if he will provide a full list of the experts who were consulted in the process of making this decision.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	47668
answer	answer is ministerial correction date of answer 29/09/2022 answer text <p>The decision not to procure Evusheld at this present time for prevention through emergency routes is based on independent clinical advice by the multi-agency RAPID C-19 and a national expert policy working group. The decision is based on a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies, including the study published on 29 July 2022. These groups concluded that there is currently insufficient evidence of benefit against Omicron variants to recommend deployment. The Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and it should now be referred to the National Institute for Health and Care Excellence for further evaluation. The Department intends to publish further details of the clinical advice received shortly.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 29/09/2022 15:03:52 answering member 4320 label Biography information for Robert Jenrick
tabling member	4769 label Biography information for Daisy Cooper

1504903

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what process is undertaken by t5he (a) NHS and (b) his Department to evaluate potential future prophylactic covid-19 treatments.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	47669
answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>The Government is undertaking a clinical trial called ‘PROTECT-V’, which is open to some immunocompromised patients. PROTECT-V tests treatments intended to reduce the risk of confirmed symptomatic COVID-19 infections in vulnerable renal and immunosuppressed patients and reduce the associated risk of hospitalisation and death.</p><p>The multi-agency RAPID C-19 and a national expert policy working group will continue to provide independent clinical advice on any potential future prophylactic COVID-19 treatments. These groups consider a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies. RAPID C-19 monitors clinical trials for emerging evidence and where treatments are proven to be clinically effective, ensures that National Health Service patients can safely receive early access.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 14:25:14 answering member 4320 label Biography information for Robert Jenrick
tabling member	4769 label Biography information for Daisy Cooper